GLP-1 drugs must now carry warning labels about rare risk of vision loss
FDA is now requiring GLP-1 weight-loss drugs to include warning information about the rare potential for vision loss. The mandate follows a review of available research and patient complaints, but the FDA did not find a direct cause-and-effect relationship between GLP-1s and vision loss.
Original Source
Read the full article at Phillyvoice →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.